Atherosclerosis and venous thromboembolism - Similarities

Kardiologia Polska

Volumn 71, Issue 12, 2013, Pages 1223-1228

  Undas, Anetta ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBIN; ANTITHROMBOCYTIC AGENT; BLOOD CLOTTING FACTOR 5 LEIDEN; FIBRIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOXYGENASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHOLIPID ANTIBODY; PLACEBO; PROSTAGLANDIN SYNTHASE; PROTEIN S; PROTHROMBIN; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; ROSUVASTATIN; THROMBOMODULIN; WARFARIN; XANTHINE OXIDASE;

ABDOMINAL OBESITY; ACUTE HEART INFARCTION; ANTICOAGULANT THERAPY; ANTIPHOSPHOLIPID SYNDROME; ANTITHROMBIN DEFICIENCY; ARTERIAL THROMBOEMBOLISM; ARTERIAL WALL THICKNESS; ARTERY CALCIFICATION; ARTERY THROMBOSIS; ARTERY WALL; ATHEROSCLEROSIS; BLOOD CLOTTING; BRAIN ISCHEMIA; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; DEEP VEIN THROMBOSIS; DIABETES MELLITUS; DISEASE PREDISPOSITION; DRUG EFFICACY; DYSLIPIDEMIA; ENVIRONMENTAL FACTOR; EPIDEMIOLOGICAL DATA; FAMILY HISTORY; FOLLOW UP; HEART INFARCTION; HEMOSTASIS; HEREDITY; HUMAN; HYPERTENSION; LIFESTYLE MODIFICATION; LOW DRUG DOSE; LUNG EMBOLISM; PATHOPHYSIOLOGY; PROTEIN C DEFICIENCY; PROTEIN EXPRESSION; PROTEIN S DEFICIENCY; REVIEW; ST SEGMENT ELEVATION; THROMBOCYTE ACTIVATION; THROMBOSIS; VENOUS THROMBOEMBOLISM;

ANIMALS; ANTICOAGULANTS; ATHEROSCLEROSIS; CAUSALITY; COMORBIDITY; DISEASE MODELS, ANIMAL; HUMANS; MYOCARDIAL INFARCTION; RISK FACTORS; VENOUS THROMBOEMBOLISM;

EID: 84890545081     PISSN: 00229032     EISSN: None     Source Type: Journal    
DOI: 10.5603/KP.2013.0322     Document Type: Review

References (54)

1. Lijfering WM, Flinterman LE, Vandenbroucke JP et al. Relationship between venous and arterial thrombosis: a review of the literature from a causal perspective. Semin Thromb Hemost, 2011; 37: 885-896.
2. Butenas S, Orfeo T, Mann K. Tissue factor in coagulation Which? Where? When? Arterioscler Thromb Vasc Biol, 2009; 29: 1989-1996.
3. Silvain J, Collet J-P, Nagaswami C et al. Composition of coronary thrombus in acute myocardial infarction. J Am Coll Cardiol, 2011; 57: 1359-1367.
4. Mazur P, Sobczyński R, Za̧bczyk M et al. Architecture of fibrin network inside thrombotic material obtained from the right atrium and pulmonary arteries during embolectomy: flow and location matter. J Thromb Thrombolysis, 2013; 35: 127-129.
5. Kleinegris MC, Ten Cate-Hoek AJ, Ten Cate H. Coagulation and the vessel wall in thrombosis and atherosclerosis. Pol Arch Med Wewn, 2012; 122: 557-566.
6. Prandoni P, Bilora F, Marciori A et al. An association between atherosclerosis and venous thrombosis. N Engl J Med, 2003; 348: 1435-1441.
7. Becattini C, Agnelli G, Prandoni P et al. A prospective study on cardiovascular events after acute pulmonary embolism. Eur Heart J, 2005; 26: 77-83.
8. Prandoni P, Ghirarduzzi A, Prins MH et al. Venous thromboembolism and the risk of subsequent symptomatic atherosclerosis. J Thromb Haemost, 2006; 4: 1891-1896.
9. Bova C, Marchiori A, Noto A et al. Incidence of arterial cardiovascular events in patients with idiopathic venous thromboembolism. A retrospective cohort study. Thromb Haemost, 2006; 96: 132-136.
10. Sorensen HT, Horvath-Puho E, Pedersen L et al. Venous thromboembolism and subsequent hospitalization due to acute arterial cardiovascular events: a 20 year cohort study. Lancet, 2007; 370: 1773-1779.
11. Young L, Ockelford P, Milne D et al. Post-treatment residual thrombus increases the risk of recurrent deep vein thrombosis and mortality. J Thromb Haemost, 2006; 4: 1919-1924.
12. Becattini C, Vedovati MC, Ageno W et al. Incidence of arterial cardiovascular events after venous thromboembolism: a systematic review and meta-analysis. J Thromb Haemost, 2010; 8: 891-897.
13. Lowe GDO. Arterial disease and venous thrombosis: are they related, and if so, what should we do about it? J Thromb Haemost, 2006; 4: 1882-1885.
14. Lind C, Flinterman C, Enga K et al. Impact of incident venous thromboembolism on future risk of arterial thrombotic disease. ISTH Congress 2013, Abstract OC 07.1.
15. Agnelli G, Becattini C. Venous thromboembolism and atherosclerosis: common denominators or different diseases? J Thromb Haemost, 2006; 4: 1886-1890.
16. Eliasson A, Bergqvist D, Bjorck M et al. Incidence and risk of venous thromboembolism in patients with verified arterial thrombosis: a population study based on 23,796 consecutive autopsies. J Thromb Haemost, 2006; 4: 1897-1902.
17. Reich LM, Folsom AR, Key NS et al. Prospective study of subclinical atherosclerosis as a risk factor for venous thromboembolism. J Thromb Haemost, 2006; 4: 1909-1913.
18. van der Hagen PB, Folsom AR, Jenny NS et al. Subclinical atherosclerosis and the risk of future venous thrombosis in the Cardiovascular Health Study. J Thromb Haemost, 2006; 4: 1903-1908.
19. Piazza G, Goldhaber SZ, Lessard DM et al. Venous thromboembolism in patients with symptomatic atherosclerosis. Thromb Haemost, 2011; 106: 1095-1102.
20. Ageno W, Becattini C, Brighton T et al. Cardiovascular risk factors and venous thromboembolism: a meta-analysis. Circulation, 2008; 117: 93-102.
21. Deguchi H, Pecheniuk N, Elias D et al. High-density lipoprotein deficiency and dyslipoproteinemia associated with venous thrombosis in men. Circulation, 2005; 112: 893-899.
22. Di Minno MN, Tufano A, Guida A et al. Abnormally high prevalence of major components of the metabolic syndrome in subjects with early-onset idiopathic venous thromboembolism. Thromb Res, 2011; 127: 193-197.
23. Mahmoodi BK, Gansevoort RT, Veeger NJ et al; Prevention of Renal and Vascular End-stage Disease (PREVEND) Study Group. Microalbuminuria and risk of venous thromboembolism. JAMA, 2009; 301: 1790-1797.
24. Zacho J, Tybjaerg-Hansen A, Nordestgaard BG. C-reactive protein and risk of venous thromboembolism in the general population. Arterioscler Thromb Vasc Biol, 2010; 30: 1672-1678.
25. Heit JA, O'Fallon WM, Petterson TM et al. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med., 2002; 162: 1245-1248.
26. Zawilska K, Bała MM, Błȩdowski P et al. [Polish guidelines for the prevention and treatment of venous thromboembolism. 2012 update]. Pol Arch Med Wewn, 2012; 122 (suppl. 2): 3-74.
27. Ye Z, Liu EH, Higgins JP et al. Seven haemostatic gene polymorphisms in coronary disease: meta-analysis of 66,155 cases and 91,307 controls. Lancet, 2006; 367: 651-658.
28. Celinska-Lowenhoff M, Iwaniec T, Alhenc-Gelas M et al. Arterial and venous thrombosis and prothrombotic fibrin clot phenotype in a Polish family with type 1 antithrombin deficiency (antithrombin Krakow). Thromb Haemost, 2011; 106: 379-381.
29. Szymańska M, Alhenc-Gelas M, Undas A. Recurrent ischemic cerebrovascular events in a patient with type I antithrombin deficiency caused by 9788 G>A splice site mutation: a case report. Blood Coagul Fibrinolysis, 2013; 24: 213-215.
30. Mahmoodi BK, Brouwer JL, Veeger NJ, van der Meer J. Hereditary deficiency of protein C or protein S confers increased risk of arterial thromboembolic events at a young age: results from a large family cohort study. Circulation, 2008; 118: 1659-1667.
31. Arnson Y, Shoenfeld Y, Alon E, Amital H. The antiphospholipid syndrome as a neurological disease. Semin Arthritis Rheum, 2010; 40: 97-108.
32. Soltész P, Szekanecz Z, Kiss E, Shoenfeld Y. Cardiac manifestations in antiphospholipid syndrome. Autoimmun Rev, 2007; 6: 379-386.
33. Sare GM, Gray LJ, Bath PM. Association between hormone replacement therapy and subsequent arterial and venous vascular events: a meta-analysis. Eur Heart J, 2008; 29: 2031-2041.
34. Fuchs TA, Brill A, Wagner DD. Neutrophil Extracellular Trap (NET) impact on deep vein thrombosis. Arterioscler Thromb Vasc Biol, 2012; 32: 1777-1783.
35. Brill A, Fuchs TA, Savchenko AS et al. Neutrophil extracellular traps promote deep vein thrombosis in mice. J Thromb Haemost, 2012; 10: 136-144.
36. von Brühl ML, Stark K, Steinhart A et al. Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo. J Exp Med, 2012; 209: 819-835.
37. Jawień J. Atherosclerosis in 2012: what is new? Pol Arch Med Wewn, 2012; 122: 170-173.
38. Budaj M, Poljak Z, Ďuriš I et al. Microparticles: a component of various diseases. Pol Arch Med Wewn, 2012; 122 (suppl. 1): 24-29.
39. Ye R, Ye C, Huang Y, Liu L, Wang S. Circulating tissue factor positive microparticles in patients with acute recurrent deep venous thrombosis. Thromb Res, 2012; 130: 253-258.
40. Suades R, Padró T, Vilahur G, Badimon L. Circulating and platelet-derived microparticles in human blood enhance thrombosis on atherosclerotic plaques. Thromb Haemost, 2012; 108: 1208-1219.
41. Szasz T, Thakali K, Fink GD, Watts SW. A comparison of arteries and veins in oxidative stress: producers, destroyers, function, and disease. Exp Biol Med (Maywood), 2007; 232: 27-37.
42. Guzik B, Chwała M, Matusik P et al. Mechanisms of increased vascular superoxide production in human varicose veins. Pol Arch Med Wewn, 2011; 121: 279-286.
43. Re G, Lanzarini C, Vaona I et al. Systemically circulating oxidative species in human deep venous thrombosis. Eur J Emerg Med, 1998; 5: 9-12.
44. Undas A, Ariëns RA. Fibrin clot structure and function: a role in the pathophysiology of arterial and venous thromboembolic diseases. Arterioscler Thromb Vasc Biol, 2011; 31: e88-e99.
45. Undas A. Acquired dysfibrinogenemia in atherosclerotic vascular disease. Pol Arch Med Wewn, 2011; 121: 310-319.
46. Undas A, Brummel-Ziedins KE, Mann KG. Statins and blood coagulation. Arterioscler Thromb Vasc Biol, 2005; 25: 287-294.
47. Glynn R, Danielson E, Fonseca F et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med, 2009; 360: 1851-1861.
48. Squizzato A, Galli M, Romualdi E et al. Statins, fibrates, and venous thromboembolism: a meta-analysis. Eur Heart J, 2010; 31: 1248-1256.
49. Becattini C, Agnelli G, Schenone A et al. Aspirin for preventing the recurrence of venous thromboembolism. N Engl J Med, 2012; 366: 1959-1967.
50. Undas A, Brummel-Ziedins KE, Mann KG. Antithrombotic properties of aspirin and resistance to aspirin: beyond strictly antiplatelet actions. Blood, 2006; 109: 2285-2292.
51. Hurlen M, Abdelnoor M, Smith P et al. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med, 2002; 347: 969-974.
52. van Stralen KJ, Le Cessie S, Rosendaal FR, Doggen CJ. Regular sports activities decrease the risk of venous thrombosis. J Thromb Haemost, 2007; 5: 2186-2192.
53. Steffen LM, Folsom AR, Cushman M et al. Greater fish, fruit and vegetable intakes are related to lower incidence of venous thromboembolism: the longitudinal investigation of thromboembolism etiology. Circulation, 2007; 115: 188-195.
54. Di Minno MN, Tufano A, Ageno W et al. Identifying high-risk individuals for cardiovascular disease: similarities between venous and arterial thrombosis in perspective. A 2011 update. Intern Emerg Med, 2012; 7: 9-13.